Vertex Pharmaceuticals Incorporated (VRTX)

NASDAQ: VRTX · USD

$530

+8.49 (+1.6%)· Recorded snapshot

英文原文ZH

翻译期间显示英文原文

此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

StockMarketAgent Research · Analyzed 2026-09-26

Our latest published analysis: VRTX rated Sell

Vertex Pharmaceuticals Incorporated's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$335 / share

Potential value

$394 / share

Upside to FV

-36.3%

from $530

Moat

9/10

Wide

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$132.4B
Revenue (ttm)	12.6B
Net income (ttm)	4.4B
EPS (ttm)	$17.2
Shares out	253.5M
P/E (trailing)	30.8x
P/E (forward)	24.1x
Volume	920,461
Beta	0.28

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 12.6B
Net income (ttm): 4.4B
EPS (ttm): $17.2
P/E (trailing): 30.8x
P/E (forward): 24.1x
Market cap: $132.4B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$7.57B	$8.93B	$9.87B	$11.02B	$12.00B	+12.2%
Gross profit	$6.67B	$7.85B	$8.61B	$9.49B	$10.27B	+11.4%
Operating income	$2.78B	$4.31B	$3.83B	$-232.9M	$4.17B	+10.7%
Net income	$2.34B	$3.32B	$3.62B	$-535.6M	$3.95B	+14.0%
EPS (diluted)	$9.01	$12.82	$13.89	$-2.08	$15.32	+14.2%
EBITDA	$2.92B	$4.44B	$4.61B	$486.3M	$4.86B	+13.6%
R&D	$3.05B	$2.66B	$3.16B	$3.63B	$3.75B	+5.3%
SG&A	$840.1M	$944.7M	$1.14B	$1.46B	$1.75B	+20.2%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	卖出
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	卖出
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	强力买入
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	卖出
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	减持
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	减持

Base and Bull scenarios

Base60%

Price target

$334.95

-36.3% from spot

The base case represents modal execution where Vertex maintains cystic fibrosis durability while ramping Journavx and Casgevy to achieve non-CF revenue milestones in FY2026. Operating margins expand gradually as launch spending normalizes, supporting sustainable high-single-digit earnings compounding.

Revenue expands steadily across FY2026 and FY2027 driven by sustained cystic fibrosis demand
Operating margin expands gradually through FY2029 as initial commercialization expenditures normalize
Non-CF products achieve commercial guidance milestones in FY2026 led by Journavx formulary access across institutional hospitals
Terminal multiple normalizes toward historical specialty biopharmaceutical averages discounted at the house cost of equity

Bull20%

Price target

$394.33

-25.1% from spot

In the upside scenario, next-generation Alyftrek transitions the global cystic fibrosis patient base seamlessly, securing monopoly cash flows past the next decade. Journavx rapidly penetrates surgical pain protocols across institutional hospital networks, and pipeline assets in renal and endocrinology deliver accelerated revenue growth, driving operating margin expansion.

Alyftrek solidifies global cystic fibrosis leadership with rapid patient transition extending patent exclusivity well past the next decade
Journavx establishes a non-opioid standard of care across major institutional hospital networks, achieving multi-billion-dollar peak revenue potential
Operating margin expands significantly on gross margin stability and operating leverage
Terminal multiple sustains near elevated valuation levels, matching trading multiples

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($334.95). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.5%	2.8%	3.0%	3.3%	3.5%
6.8%	$345	$345	$345	$345	$345
7.3%	$340	$340	$340	$340	$340
7.8%	$335	$335	$335	$335	$335
8.3%	$330	$330	$330	$330	$330
8.8%	$326	$326	$326	$326	$326

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E24.1

P25 n/aP50 n/aP75 n/a

Trailing P/E30

P25 n/aP50 n/aP75 n/a

ROE23.5

P25 n/aP50 n/aP75 n/a

ROIC28.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All VRTX indicators

Market & fundamental data

Available fields

276

Groups with data

Currency

USD

Showing 276 of 276 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0000875320
Company name	Vertex Pharmaceuticals Incorporated
Country	United States
Country code	US
CUSIP number	92532F100
Earnings date	2026-11-02
Earnings time	amc
Employees	6,400
Employees change	300
Employees growth	4.92%
Enterprise value	$122.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1989
In index	SP500, NASDAQ100
Industry	Biotechnology
IPO date	1991-07-24
Is primary listing	Yes
Is SPAC	No
ISIN number	US92532F1003
Last 10-K release date	2026-02-13
Last earnings date	2026-08-03
Last refreshed	2026-10-28
Last stock split date	2000-08-24
Last stock split type	Forward
Market cap	$134.2B
Market cap category	Large-Cap
Next earnings date	2026-11-02
Options	Yes
Price	$529.53
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	VRTX
U.S. state	Massachusetts
Website	https://www.vrtx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	27.83x
Average P/E ratio (10Y)	50.03x
Average P/E ratio (3Y)	28.04x
Average P/E ratio (5Y)	26.01x
Earnings yield	3.24%
EV/Earnings	27.73x
EV/EBIT	24.88x
EV/EBITDA	23.95x
EV/FCF	32.18x
EV/Sales	9.71x
FCF / EV yield	3.11%
FCF yield	2.84%
Forward EV/Sales	8.73x
Forward P/E	35.68x
Forward P/S	9.56x
Graham number	175.77682
Graham upside	-66.71%
Lynch fair value	$295.61
Lynch upside	-44.01%
P/(FCF - SBC) ratio	43.07x
P/(OCF - SBC) ratio	37.14x
P/B ratio	6.52x
P/E ratio	30.82x
P/FCF ratio	35.25x
P/OCF ratio	31.17x
P/S ratio	10.63x
PEG ratio	2.8x
Price / tangible book value	7.14x
Price/EBITDA ratio	26.24x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	39%
EBITDA margin	40.52%
Effective tax rate	16.48%
FCF margin	30.16%
Gross margin	54.96%
Operating margin	39%
Pretax margin	41.9%
Profit margin	35%
Profit per employee	$688,313
Profitable quarters	8
Profitable years	1
Revenue per employee	$2M
ROA	11.93%
ROA (5Y)	14.82%
ROCE	20.9%
ROE	23.54%
ROE (5Y)	19%
ROIC	28.8%
ROIC (5Y)	37.75%
SBC / revenue	5.47%
Tax / revenue	6.91%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	22.12%
EPS growth (Q)	8.02%
EPS growth (QoQ)	7.21%
EPS growth 3Y	9.92%
EPS growth 5Y	17.77%
EPS growth quarters	5
EPS growth years	1
FCF growth	8.47%
FCF growth (Q)	9.25%
FCF growth (QoQ)	-21.74%
FCF growth 3Y	-0.71%
FCF growth 5Y	16.39%
Gross profit growth	15.3%
Gross profit growth (Q)	17.23%
Gross profit growth 3Y	8.01%
Gross profit growth 5Y	11.52%
Net income growth	21.1%
Net income growth (Q)	6.48%
Net income growth (QoQ)	6.63%
Net income growth 3Y	9.4%
Net income growth 5Y	17.2%
Net income growth quarters	5
Net income growth years	1
OCF growth	11.61%
OCF growth (Q)	4.87%
OCF growth (QoQ)	-21.2%
OCF growth 3Y	1.81%
OCF growth 5Y	15.15%
Operating income growth	10.85%
Operating income growth (Q)	9.92%
Operating income growth 3Y	3.16%
Operating income growth 5Y	8.75%
Revenue growth	10.23%
Revenue growth (Q)	12.45%
Revenue growth (QoQ)	11.62%
Revenue growth 10Y	23.24%
Revenue growth 3Y	9.81%
Revenue growth 5Y	13.5%
Revenue growth quarters	33
Revenue growth years	11

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-496.8M
Depreciation and amortization	$190.9M
EBIT	$4.9B
EBITDA	$5.1B
EPS	$17.18
FCF per share	$14.98
Financing cash flow	$-2.2B
Free cash flow	$3.8B
Free cash flow minus SBC	$3.1B
Gross profit	$6.9B
Income taxes	$869.3M
Investing cash flow	$-882.8M
Net borrowing	$-5.4M
Net cash flow	$1.2B
Net income	$4.4B
Operating cash flow minus SBC	$3.6B
Operating income	$4.9B
Revenue	$12.6B
Stock-based compensation	$689.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	11.58
Book value per share	$79.92
Debt / EBITDA	0.37
Debt / equity	0.1
Debt / FCF	0.52
Goodwill	$1.1B
Interest coverage	369.14
Long-term assets	$14.9B
Long-term liabilities	$3.2B
Net cash (debt)	$11.7B
Net cash / market cap	8.72%
Net cash growth	11.07%
Net debt / EBITDA	-2.29
Net debt / equity	-0.58
Net debt / FCF	-3.07
Piotroski F-Score	5
Property, plant and equipment	$3.3B
Shareholders' equity	$20.2B
Tangible book value	$18.7B
Tangible book value per share	$74.00
Total assets	$27.4B
Total cash	$7.9B
Total debt	$2B
Total liabilities	$7.2B
WACC	5.72%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.49
Current assets	$12.5B
Current liabilities	$3.9B
Current ratio	3.19
Inventory turnover	3.47
Net working capital	$753.4M
Quick ratio	2.54
Working capital	$8.6B
Working capital turnover	1.69

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.85%
Dividend yield	0%
Shareholder yield	0.85%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	599.16%
10Y return CAGR	21.47%
10Y total return	599.16%
150-day SMA	$481.53
15Y price change	1,145.28%
15Y return CAGR	18.31%
15Y total return	1,145.28%
1D price change	1.63%
1M price change	0.77%
1M total return	0.77%
1W price change	3.03%
1W total return	3.03%
1Y price change	26.2%
1Y return CAGR	26.22%
1Y total return	26.2%
20-day SMA	$510.22
200-day SMA	$478.24
20Y price change	1,204.08%
20Y return CAGR	13.7%
20Y total return	1,204.08%
3M price change	10.7%
3M total return	10.7%
3Y price change	49.25%
3Y return CAGR	14.28%
3Y total return	49.25%
50-day SMA	$523.09
50-day SMA vs 200-day SMA	50over200
52-week high	$560.25
52-week high date	2026-09-03
52-week low	$403.16
52-week low date	2025-11-04
5Y price change	193.05%
5Y return CAGR	23.99%
5Y total return	193.05%
6M price change	24.47%
6M total return	24.47%
All-time high	$560.25
All-time high date	2026-09-03
All-time low	$3.25
All-time low date	1993-02-24
Average true range (ATR)	$14.29
Average volume	1.2M
Beta (1Y)	0.41
Beta (2Y)	0.44
Beta (5Y)	0.28
Change from 52-week high	-5.48%
Change from 52-week low	31.35%
Change from all-time high	-5.36%
Change from all-time low	16,215.08%
Change from open	2.42%
Day's gap	-0.77%
Dollar volume	$487.4M
High price	$534.83
Low price	$516.38
Monthly RSI	60.27
Open price	$517.00
Position in 52-week range	71.27%
Premarket change	-0.43%
Premarket close	$521.03
Premarket price	$518.80
Previous close	$521.03
Price vs 150-day SMA	10.12%
Price vs 20-day SMA	3.92%
Price vs 200-day SMA	10.87%
Price vs 50-day SMA	1.37%
Relative volume	0.74
RSI	57.54
Sharpe ratio	0.81
Sharpe ratio (3Y)	0.43
Sharpe ratio (5Y)	0.73
Sortino ratio	1.54
Sortino ratio (3Y)	0.76
Sortino ratio (5Y)	1.23
Volume	920.5K
Weekly RSI	60.04
YTD price change	16.96%
YTD total return	16.96%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	252.7M
Float percentage	99.69%
Shares change (QoQ)	-0.43%
Shares change (YoY)	-0.85%
Shares held by insiders	0.2%
Shares held by institutions	97.13%
Shares outstanding	253.5M
Short % of float	1.78%
Short % of shares	1.78%
Short ratio	4.4 days

Deeper analysis on VRTX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this VRTX report

What is the latest published VRTX stock rating?

Vertex Pharmaceuticals Incorporated is shown with Sell in the latest published report, analyzed 2026-09-26. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full VRTX analysis?

The full latest published report, analyzed 2026-09-26, lives at /stocks/VRTX/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for VRTX?

The latest published report analyzed 2026-09-26 gives VRTX a fair value of USD 335 and a potential value of USD 394. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the VRTX page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-09-26). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

SellVRTX · Fair value $335-36.3%

Read full analysis →

Vertex Pharmaceuticals Incorporated (VRTX)

Our latest published analysis: VRTX rated Sell

Price

Financial snapshot

Fair-value bridge

Latest news · VRTX

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All VRTX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on VRTX

Frequently asked questions

评级历史

Category	Score	Reading
Valuation	1.5
Management	8.5
Balance Sheet	8.5
Profitability	7.5
Revenue Growth	6.0
Risk Assessment	9.0
Competitive Moat	9.0
Earnings Quality	6.5
Capital Efficiency	7.5